All In Biotech

Drug Trial Radar · NCT04738812

Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

ANRS 12424: Determination of Adequate Tuberculosis Regimen in Adults and Adolescents Hospitalized With HIV-associated Severe Immune Suppression (CD4 ≤ 100 Cells/µL): the DATURA Trial.

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,330

Actual

Start

Apr 21, 2022

Primary completion

Nov 12, 2025

Study completion Nov 12, 2025

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
European Union; European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Feb 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: * Intensified TB treatment regimen: increased doses of rifampicin and isoniazid together with standard-dose of pyrazinamide and ethambutol for 8 weeks in addition to prednisone for 6 weeks and albendazole for 3 days * WHO standard TB treatment regimen. The continuation phase of TB treatment will be identical in the two arms: 4 months of rifampicin and isoniazid at standard doses.

Conditions

  • Tuberculosis
  • HIV-1-infection
  • Immuno-Deficiency

Interventions

  • Intensified TB treatment (initial phase)Drug

    8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R. 6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg.

  • WHO standard TB treatment (initial phase)Drug

    8 weeks of RHEZ with FDC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of all causes deathTime frame: Up to 48 weeks

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • National Center for HIV/AIDS, Dermatology and STD (NCHADS)

    Phnom Penh, Cambodia

  • Jamot Hospital

    Yaoundé, Cameroon

  • Ignace Deen Hospital

    Conakry, Guinea

  • MACHAVA Hospital

    Maputo, Mozambique

  • Mbarara Regional Referral hospital

    Mbarara, Uganda

  • University Teaching Hospital

    Lusaka, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.